{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:41:55Z","timestamp":1793072515253,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2018.10.033","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T12:33:55Z","timestamp":1542285235000},"page":"7427-7436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Defining a correlate of protection for chikungunya virus vaccines"],"prefix":"10.1016","volume":"37","author":[{"given":"Gregg N.","family":"Milligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Schnierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.C.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.033_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tmaid.2017.01.004","article-title":"Long-term sequelae of chikungunya virus disease: a systematic review","volume":"15","author":"van Aalst","year":"2017","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.10.033_b0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trstmh.2009.07.031","article-title":"Atypical manifestations of chikungunya infection","volume":"104","author":"Rajapakse","year":"2010","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.10.033_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050060","article-title":"Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion","volume":"5","author":"Gerardin","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0025","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.vaccine.2016.03.076","article-title":"Status of research and development of vaccines for chikungunya","volume":"34","author":"Smalley","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0030","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1016\/j.vaccine.2017.07.065","article-title":"Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus","volume":"35","author":"Yang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0035","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4161\/hv.28639","article-title":"Fast vaccine design and development based on correlates of protection (COPs)","volume":"10","author":"van Els","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.10.033_b0040","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1016\/j.vaccine.2008.06.012","article-title":"FDA\/NIH\/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10\u201311, 2007","volume":"26","author":"Eichelberger","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0045","first-page":"97","article-title":"Immune correlates of protection against influenza in the human challenge model","volume":"115","author":"Treanor","year":"2003","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2018.10.033_b0050","unstructured":"EMA\/CHMP. Guideline on the scientific application and the practical arrangements necessary to implement Regulation (EC) No 507\/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004. European Medicines Agency; 2016."},{"key":"10.1016\/j.vaccine.2018.10.033_b0055","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1073\/pnas.1515558112","article-title":"Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity","volume":"112","author":"Long","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.10.033_b0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coviro.2016.02.007","article-title":"Interspecies transmission and chikungunya virus emergence","volume":"16","author":"Tsetsarkin","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004960","article-title":"Antigenic variation of East\/Central\/South African and Asian Chikungunya virus genotypes in neutralization by immune sera","volume":"10","author":"Chua","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0070","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","article-title":"A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes","volume":"214","author":"Goo","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0075","unstructured":"WHO. Chikungunya \u2013 fact sheet. World Health Organization; 2017."},{"key":"10.1016\/j.vaccine.2018.10.033_b0080","doi-asserted-by":"crossref","first-page":"vex010","DOI":"10.1093\/ve\/vex010","article-title":"Understanding the evolution and spread of chikungunya virus in the Americas using complete genome sequences","volume":"3","author":"Sahadeo","year":"2017","journal-title":"Virus Evol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0085","unstructured":"PAHO. Number of Reported Cases of Chikungunya Fever in the Americas, by Country or Territory \u2013 2017 -Epidemiological Week\/EW 51.: Pan American Health Organization; 2017"},{"key":"10.1016\/j.vaccine.2018.10.033_b0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nmni.2017.05.008","article-title":"First Chikungunya outbreak in Pakistan: a trail of viral attacks","volume":"19","author":"Mallhi","year":"2017","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.vaccine.2018.10.033_b0095","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1473-3099(17)30074-9","article-title":"Outbreak of chikungunya in Pakistan","volume":"17","author":"Rauf","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0100","unstructured":"ECDC. Communicable Disease Threats Report, Week 36, 3-9 September 2017. Stockholm: European Center for Disease Prevention and Control; 2017."},{"key":"10.1016\/j.vaccine.2018.10.033_b0105","unstructured":"ECDC. Cluster of autochthonous chikungunya cases in France - 23 August 2017. Stockholm: European Center for Disease Prevention and Control; 2017."},{"key":"10.1016\/j.vaccine.2018.10.033_b0110","unstructured":"ECDC. Communicable disease threats report, 17\u201323 December 2017, week 51; 2017."},{"key":"10.1016\/j.vaccine.2018.10.033_b0115","first-page":"5","article-title":"Autochthonous outbreak, Lazio Region, Italy","volume":"2017","author":"Carletti","year":"2017","journal-title":"Genome Announc"},{"key":"10.1016\/j.vaccine.2018.10.033_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004261","article-title":"IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity","volume":"4","author":"Ng","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.10.033_b0125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1084\/jem.20090851","article-title":"Type I IFN controls chikungunya virus via its action on nonhematopoietic cells","volume":"207","author":"Schilte","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0040029","article-title":"A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease","volume":"4","author":"Couderc","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.10.033_b0135","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1128\/JVI.02603-09","article-title":"Chikungunya virus arthritis in adult wild-type mice","volume":"84","author":"Gardner","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1445-5994.1985.tb04048.x","article-title":"The inflammatory response in the synovium of a patient with Ross River arbovirus infection","volume":"15","author":"Hazelton","year":"1985","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1445-5994.1981.tb04226.x","article-title":"Cytology of synovial effusions in epidemic polyarthritis","volume":"11","author":"Fraser","year":"1981","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0150","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.4049\/jimmunol.0900255","article-title":"Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response","volume":"184","author":"Hoarau","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0155","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI40104","article-title":"Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages","volume":"120","author":"Labadie","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.10.033_b0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/infdis\/jiq006","article-title":"The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation","volume":"204","author":"Wauquier","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/infdis\/jiq042","article-title":"Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor","volume":"203","author":"Chow","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0170","first-page":"142","article-title":"Chronic inflammatory arthritis with persisting bony erosions in patients following chikungunya infection","volume":"140","author":"Chaaithanya","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2018.10.033_b0175","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1002\/art.34631","article-title":"Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis","volume":"64","author":"Nakaya","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2018.10.033_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084695","article-title":"Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005\u20132006 in La Reunion Island","volume":"8","author":"Hoarau","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.10.033_b0185","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2009.04.015","article-title":"CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus","volume":"27","author":"Yun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.1401833","article-title":"CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice","volume":"194","author":"Burrack","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0195","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1128\/JVI.72.6.5146-5153.1998","article-title":"Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages","volume":"72","author":"Linn","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0200","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2013.05.059","article-title":"Deciphering the protective role of adaptive immunity to CHIKV\/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model","volume":"31","author":"Chu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0205","doi-asserted-by":"crossref","first-page":"13878","DOI":"10.1128\/JVI.02666-13","article-title":"Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response","volume":"87","author":"Hawman","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajpath.2010.11.018","article-title":"A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence","volume":"178","author":"Morrison","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0215","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1128\/JVI.80.2.737-749.2006","article-title":"Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis","volume":"80","author":"Morrison","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.1202177","article-title":"A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice","volume":"190","author":"Teo","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0225","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of Chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0230","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","article-title":"Prophylaxis and therapy for Chikungunya virus infection","volume":"200","author":"Couderc","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.10.033_b0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/infdis\/jis674","article-title":"Use of human monoclonal antibodies to treat Chikungunya virus infection","volume":"207","author":"Fric","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0250","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.4049\/jimmunol.1003139","article-title":"Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency","volume":"186","author":"Warter","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002423","article-title":"A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease","volume":"7","author":"Selvarajah","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0260","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","article-title":"Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus","volume":"18","author":"Smith","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2018.10.033_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0270","doi-asserted-by":"crossref","first-page":"13005","DOI":"10.1128\/JVI.01780-12","article-title":"Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development","volume":"86","author":"Kam","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0275","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1515\/cclm-2013-0363","article-title":"Analysis of antibody response (IgM, IgG, IgG3) to Chikungunya virus using panel of peptides derived from envelope protein for serodiagnosis","volume":"52","author":"Verma","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0280","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0285","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix283","article-title":"Clinical, serological and Virological analysis of 572 chikungunya patients during the years 2010\u20132013 from India","author":"Jain","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0290","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.4049\/jimmunol.153.11.4948","article-title":"Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2","volume":"153","author":"Kawano","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nmni.2015.04.002","article-title":"Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy","volume":"7","author":"Pierro","year":"2015","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.vaccine.2018.10.033_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004281","article-title":"Long-lasting immune protection and other epidemiological findings after Chikungunya emergence in a Cambodian Rural Community, April 2012","volume":"10","author":"Galatas","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1743-422X-11-183","article-title":"Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand","volume":"11","author":"Nitatpattana","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.10.033_b0310","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/vbz.2014.1681","article-title":"Therapeutics and vaccines against chikungunya virus","volume":"15","author":"Ahola","year":"2015","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0315","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1093\/infdis\/jiw271","article-title":"Development of vaccines for Chikungunya Fever","volume":"214","author":"Erasmus","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0320","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and therapeutic options to control Chikungunya virus","volume":"31","author":"Powers","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2018.10.033_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000928","article-title":"A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates","volume":"5","author":"Mallilankaraman","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0330","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1016\/j.vaccine.2012.07.072","article-title":"Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus","volume":"30","author":"Kumar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0335","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.celrep.2015.11.043","article-title":"Neutralizing monoclonal antibodies block Chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis","volume":"13","author":"Jin","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2018.10.033_b0340","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2015.10.050","article-title":"Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress","volume":"163","author":"Fox","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2018.10.033_b0345","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AEM.19.2.321-325.1970","article-title":"Chikungunya virus vaccine prepared by Tween-ether extraction","volume":"19","author":"Eckels","year":"1970","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0350","first-page":"229","article-title":"Immunological properties of Chikungunya virus and its components","volume":"13","author":"Igarashi","year":"1970","journal-title":"Biken J"},{"key":"10.1016\/j.vaccine.2018.10.033_b0355","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.107.3.643","article-title":"Production and evaluation of a formalin-killed Chikungunya vaccine","volume":"107","author":"Harrison","year":"1971","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0360","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1128\/AEM.23.5.951-952.1972","article-title":"Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures","volume":"23","author":"White","year":"1972","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0365","first-page":"559","article-title":"Immunogenicity of purified, inactivated chikungunya virus in monkeys","volume":"48","author":"Nakao","year":"1973","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2018.10.033_b0370","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/j.vaccine.2009.02.062","article-title":"Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus","volume":"27","author":"Tiwari","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0375","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/smll.201000331","article-title":"Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice","volume":"6","author":"Prow","year":"2010","journal-title":"Small"},{"key":"10.1016\/j.vaccine.2018.10.033_b0380","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1016\/j.vaccine.2015.07.099","article-title":"Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm","volume":"33","author":"Rudd","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0595","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4269\/ajtmh.1967.16.786","article-title":"Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues","volume":"16","author":"Harrison","year":"1967","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.10.033_b0600","first-page":"119","article-title":"Persistence in humans of antibody after immunization with four alphavirus vaccines","volume":"3","author":"DeMeio","year":"1979","journal-title":"Asian J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0385","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","article-title":"Development of an attenuated strain of chikungunya virus for use in vaccine production","volume":"4","author":"Levitt","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0390","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","article-title":"Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218","volume":"62","author":"Edelman","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.10.033_b0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002142","article-title":"Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism","volume":"7","author":"Plante","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.10.033_b0400","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1128\/JVI.03357-12","article-title":"Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL\/6J mice","volume":"87","author":"Piper","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0405","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1128\/JVI.03453-13","article-title":"Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice","volume":"88","author":"Hallengard","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002719","article-title":"Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design","volume":"8","author":"Gardner","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0415","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nm.4253","article-title":"A chikungunya fever vaccine utilizing an insect-specific virus platform","volume":"23","author":"Erasmus","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0420","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1128\/JVI.00844-11","article-title":"Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response","volume":"85","author":"Wang","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0425","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.vaccine.2008.07.054","article-title":"Chimeric alphavirus vaccine candidates for chikungunya","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0430","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0435","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0440","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1128\/JVI.01860-12","article-title":"A chimeric vesiculo\/alphavirus is an effective alphavirus vaccine","volume":"87","author":"Chattopadhyay","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0445","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","article-title":"A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003101","article-title":"Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge","volume":"8","author":"van den Doel","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002970","article-title":"A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice","volume":"8","author":"Weger-Lucarelli","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0460","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1016\/j.vaccine.2008.03.060","article-title":"Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus","volume":"26","author":"Muthumani","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0465","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/infdis\/jiu114","article-title":"DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice","volume":"209","author":"Tretyakova","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0470","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/infdis\/jiw111","article-title":"Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus","volume":"214","author":"Muthumani","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0475","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1128\/JVI.01926-14","article-title":"Prime-boost immunization strategies against Chikungunya virus","volume":"88","author":"Hallengard","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective chikungunya virus-like particle vaccine produced in insect cells","volume":"7","author":"Metz","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0485","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1016\/j.vaccine.2013.09.045","article-title":"Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits","volume":"31","author":"Metz","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004782","article-title":"Expression and characterization of yeast derived Chikungunya Virus Like Particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate","volume":"10","author":"Saraswat","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0495","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.10.033_b0500","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.10.033_b0505","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.virusres.2012.05.004","article-title":"Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1\/Th2 response and virus-neutralizing antibodies in mice","volume":"167","author":"Khan","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.10.033_b0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003684","article-title":"A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice","volume":"9","author":"Weber","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0515","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.83527","article-title":"Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus","volume":"2","author":"Roques","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2018.10.033_b0520","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/514240","article-title":"Immunologic interference from sequential administration of live attenuated alphavirus vaccines","volume":"177","author":"McClain","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2014.02.001","article-title":"A neutralization assay for chikungunya virus infections in a multiplex format","volume":"201","author":"Weber","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.10.033_b0530","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/1743-422X-10-235","article-title":"Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout","volume":"10","author":"Glasker","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.10.033_b0535","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/pathogens4030662","article-title":"Nonhuman primate models of Chikungunya virus infection and disease (CHIKV NHP Model)","volume":"4","author":"Broeckel","year":"2015","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2018.10.033_b0540","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/infdis\/jiu014","article-title":"Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose","volume":"209","author":"Roy","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.033_b0545","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1016\/j.vaccine.2011.09.125","article-title":"Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial","volume":"29","author":"Aichinger","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0550","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1016\/j.vaccine.2011.03.089","article-title":"Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection","volume":"29","author":"Holzer","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0555","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1016\/j.vaccine.2007.01.103","article-title":"The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans","volume":"25","author":"Kistner","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0560","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CVI.00546-14","article-title":"An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial","volume":"22","author":"Wressnigg","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.10.033_b0565","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4269\/ajtmh.1967.16.782","article-title":"Patterns of viremia and antibody observed in rhesus monkeys inoculated with chikungunya and other serologically related group A arboviruses","volume":"16","author":"Binn","year":"1967","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.10.033_b0570","unstructured":"WHO. WHO Expert Committee on Biological Standardization, Sixty-Seventh Report. WHO Technical Report Series; 2017. p. 75\u20136."},{"key":"10.1016\/j.vaccine.2018.10.033_b0575","doi-asserted-by":"crossref","first-page":"26097","DOI":"10.1038\/srep26097","article-title":"Early clearance of Chikungunya virus in children is associated with a strong innate immune response","volume":"6","author":"Simarmata","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.10.033_b0580","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2011.01.108","article-title":"A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.10.033_b0585","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01970-16","article-title":"Mutation of the N-terminal region of Chikungunya virus capsid protein: implications for vaccine design","volume":"8","author":"Taylor","year":"2017","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2018.10.033_b0590","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.ymthe.2017.06.017","article-title":"Production of a Chikungunya vaccine using a CHO cell and attenuated viral-based platform technology","volume":"25","author":"Eldi","year":"2017","journal-title":"Mol Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:13:52Z","timestamp":1694045632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":120,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X18313999"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining a correlate of protection for chikungunya virus vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}